Braunstein, MD, PhD, FACP, and hematology/oncology fellow Olivia Main, MD, talk about their choices for a patient with ...

According to the data from the 30-month follow-up, overall survival (OS) rates were 76% for subjects ... for adults with ...

Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...

The department used its new system for determining whether a condition is service-connected to give affected veterans access ...

Multiple myeloma is a type of cancer where plasma ... of anemia or kidney failure wasn’t associated with a worsened survival rate. Researchers concluded that the development of bone disease ...

In 1998, the five-year survival rate for multiple myeloma was 34.6%. That means that approximately 35 of 100 people with the disease were alive five years after their diagnosis. By the early 2000s ...

SAN DIEGO -- More than 70% of patients with heavily pretreated multiple myeloma responded ... for relapsed/refractory myeloma. The studies showed response rates of 31% to 40%, median PFS of ...

Background: Autologous stem cell transplantation (autoSCT) has an important role in the treatment of patients with symptomatic multiple ... survival. Treatment options for myeloma have expanded ...

Thalidomide was the first immunomodulatory agent approved for use in myeloma. Although highly ... Overall response rate; OS: Overall survival; PFS: Progression-free survival; PR: Partial response ...

In a real-world study involving patients with standard-risk, newly-diagnosed multiple myeloma (NDMM), there was no significant ... involving whether tandem ASCT improves progression-free survival (PFS ...

The CAR-T cell therapy Carvykti has been shown to be effective among patients outside the confines of a clinical trial.

Johnson & Johnson seeks US & EU approvals for Darzalex Faspro/Darzalex as subcutaneous monotherapy for high-risk smoldering multiple myeloma: Raritan, New Jersey Monday, November ...